Emerging Role of Fluciclovine and Other Next Generation PET Imaging Agents in Prostate Cancer Management
- 11 Downloads
Purpose of Review
Prostate cancer recurrence after definitive therapy is not uncommon. Recurrent disease is first detected by the elevation of prostate specific antigen (PSA) and may often be radiographically occult. The use of molecular imaging for the localization and staging of recurrent prostate cancer is promising. 18F-Fluciclovine is a synthetic amino acid analog positron emission tomography (PET) tracer which has demonstrated great utility in the evaluation of patients with suspected recurrence disease. Other newer PET tracers such 68Ga/18F-PSMA-ligands are being investigated for prostate imaging with promising results. The purpose of this article is to review the emerging role of fluciclovine in clinical practice for patients with prostate cancer.
Since the approval of fluciclovine by the Food and Drug Administration, the modality is widely used in the USA for patients with suspect disease recurrence. With the coming approval of newer generation of PET tracers, it is important to understand the unique mechanism of action and the diagnostic performance of fluciclovine PET/CT in prostate cancer imaging to allow better allocation of the radiotracers.
This review article provides a broad literature review of the current and the future potential role of fluciclovine PET/CT in prostate cancer imaging.
Keywords18F-Fluciclovine FACBC Prostate cancer PET/CT Amino acids
Compliance with Ethical Guidelines
Conflict of interest
Bital Savir-Baruch: Grant sponsored by Blue Earth Diagnostics; Philip, Lecturer. The other authors declare that they have no conflict of interest.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Information, A.C.S.M. Key statistics for prostate cancer. 5 Jan 2017;. Accessed 16 Feb 2016. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.
- 2.Cookson MS, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5.PubMedGoogle Scholar
- 3.Gleason, D.F. and G.T. Mellinger, Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974. J Urol, 2002. 167(2 Pt 2): p. 953-8; discussion 959.Google Scholar
- 10.Blue Earth Diagnostics|U.S. FDA Approves Blue Earth Diagnostics’ AxuminTM (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer—Blue Earth Diagnostics.Google Scholar
- 18.Savir-Baruch B, et al. Diagnostic performance of synthetic amino acid anti-3-[18F] FACBC PET in recurrent prostate carcinoma utilizing single-time versus dual-time point criteria. J Nucl Med. 2014;55(supplement 1):21.Google Scholar
- 27.•• Turkbey B, et al. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology. 2014;270(3):849–56. A prospective study demonstrating the limitation of fluciclovine PET/CT scan in the evaluation of patients with primary prostate cancer. PubMedGoogle Scholar
- 38.•• Schuster DM, et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2014;191(5):1446–53. The diagnostic performance of fluciclovine PET/CT scan in patients with suspected prostate cancer recurrence. Google Scholar
- 39.Savir-Baruch B, et al. Anti-FACBC uptake pattern in the prostate affects positive predictive value and is associated with the presence of brachytherapy seeds. J Nucl Med. 2013;54(2_MeetingAbstracts):346.Google Scholar
- 40.Odewole OA, et al. Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging. 2016;43(10):177.Google Scholar
- 43.• Nanni C, et al. F-FACBC (anti1-amino-3-F-fluorocyclobutane-1-carboxylic acid) versus C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2016;43(9):1601–10. The comparison of Choline to fluciclovine. An intrapatient analysis. Google Scholar
- 45.Fendler W, et al. Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: preliminary results from a phase 2/3 prospective trial. J Clin Oncol. 2018;36(15):5001.Google Scholar
- 49.• Savir-Baruch B, et al. ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin Nucl Med. 2018;43(12):909–17. The ACR practice parameters for the performance of fluciclovine PET/CT. Google Scholar
- 51.Lovrec P, et al. Factors influencing the positivity rate of commercial 18F-Fluciclovine imaging in men with suspected recurrent prostate cancer. J Nucl Med. 2018;59(supplement 1):1470.Google Scholar
- 53.Offermann A, et al. Prognostic value of the new prostate cancer international society of urological pathology grade groups. Front Med. 2017;4:157.Google Scholar
- 57.Lovec P, et al. Positive findings on 18F-fluciclovine PET/CT in patients with suspected recurrent prostate cancer and PSA levels < 0.5 and < 0.3 ng/ml. Int J Radiat Oncol Biol Phys. 2018;102(3):161.Google Scholar
- 65.•• Andriole GL, et al. The impact of positron emission tomography with (18)F-fluciclovine on the management of patients with biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol. 2018;201(2):322–31. The LOCATE study results describe a significant change in management in patients with biochemical recurrent prostate cancer. Google Scholar
- 68.Gandaglia G, et al. Short- and long-term outcomes of salvage lymph node dissection in patients with clinically recurrent prostate cancer. Eur Urol. 2017;35(6):255.Google Scholar
- 72.Linxweiler J, et al. Robotic salvage lymph node dissection in prostate cancer after PSMA- or Choline-PET/CT: operative and early oncological results. Eur Urol Suppl. 2018;17(2):e577–8.Google Scholar
- 75.•• Calais J, et al. Comparison of (68)Ga-PSMA-11 and (18)F-fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J Nucl Med. 2018;59(5):789–94. Preliminary evidence that 68Ga-PSMA-11 PET/CT scan may have a better detection rate compared to fluciclovine PET/CT scan. Google Scholar